{"nctId":"NCT04198363","briefTitle":"A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection","startDateStruct":{"date":"2020-04-30","type":"ACTUAL"},"conditions":["Helicobacter Pylori"],"count":510,"armGroups":[{"label":"Vonoprazan 20 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Vonoprazan","Drug: Amoxicillin","Drug: Clarithromycin","Drug: Bismuth Potassium citrate"]},{"label":"Esomeprazole 20 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Amoxicillin","Drug: Clarithromycin","Drug: Bismuth Potassium citrate","Drug: Esomeprazole"]}],"interventions":[{"name":"Vonoprazan","otherNames":["TAK-438"]},{"name":"Amoxicillin","otherNames":[]},{"name":"Clarithromycin","otherNames":[]},{"name":"Bismuth Potassium citrate","otherNames":[]},{"name":"Esomeprazole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1\\. Helicobacter pylori (HP)-positive participants as determined by \\^13C-urea breath test (\\^13C-UBT) at the start of the study (Visit 1 \\[screening\\]) and who require HP eradication in Physician judgment.\n\nExclusion Criteria:\n\n1. Participant had any of the following conditions at the start of the study (Visit 1, screening): acute upper gastrointestinal bleeding, active gastric ulcer (GU) or duodenal ulcer (DU) characterized by defective mucos with white coating (with or without adherent blood clots) 3 mm or more in size, acute gastric mucosal lesion (AGML), or acute duodenal mucosal lesion (ADML). However, participants with gastritis, gastric or duodenal erosion are permitted to participate.\n2. Participants with Zollinger-Ellison syndrome or gastric acid hypersecretion or those with a history of gastric acid hypersecretion.\n3. Participant has a history of malignancy or was treated for malignancy within 5 years before the start of the screening visit (the participant may be included in the study if he/she has cured cutaneous basal cell carcinoma or cervical carcinoma in situ).\n4. Participant has a known acquired immunodeficiency syndrome or hepatitis infection, including hepatitis virus carriers (hepatitis B surface antigen \\[HBsAg\\] or hepatitis C virus \\[HCV\\]- antibody-positive).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Helicobacter Pylori Positive (HP+) Participants With Successful HP Eradication at Week 4 Post-Treatment","description":"HP infection status was determined by \\^13C Urea Breath Test (\\^13C-UBT). The urea breath test is used to detect infection with HP, a bacteria associated with stomach ulcers, by testing individual breath samples in a central laboratory. The percentages are rounded off to report the nearest ten.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.8","spread":null},{"groupId":"OG001","value":"86.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":256},"commonTop":["Dysgeusia","Protein urine present","Hepatic function abnormal","Faeces discoloured"]}}}